The True Face of the Revolution in Oncology Drug Development: A Personal Reflection

E-ISSN： 2212-3938|2|1|31-35

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.2, Iss.1, 2007-01, pp. : 31-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biomarkers in oncology drug development: rescuers or troublemakers?

By Marrer Estelle Dieterle Frank

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 11, 2008-11 ,pp. : 1391-1402

Informa Healthcare

Access to resources Recommend Favorite

Dynamic Contrast-Enhanced MRI in Oncology Drug Development

Current Clinical Pharmacology, Vol. 2, Iss. 2, 2007-05 ,pp. : 111-122

Bentham Science Publishers

Access to resources Recommend Favorite

Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective

Current Pharmaceutical Design, Vol. 15, Iss. 9, 2009-03 ,pp. : 957-965

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacodynamic Biomarkers in Model-Based Drug Development in Oncology

Current Clinical Pharmacology, Vol. 6, Iss. 1, 2011-02 ,pp. : 30-40

Bentham Science Publishers

Access to resources Recommend Favorite

Current Issues in Oncology Drug Development, with a Focus on Phase II Trials

By Sargent Daniel

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 556-562

Taylor & Francis Ltd

Access to resources Recommend Favorite